RxDoctor Payments Data

Christopher Tanner, NP

Family · Flint, MINPI 1922566728

Payments from drug & device makers

$1,714in general payments, 2019–2025

Across 92 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291
  • Otsuka America Pharmaceutical, Inc.$250
  • AstraZeneca$206
  • Sunovion Pharmaceuticals Inc.$103
  • Novo Nordisk$88
  • Lundbeck LLC$86
  • plus $689 from 17 others

What the payments were for

  • Food & beverage$1,714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,714 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$8,981
Medicare patients
62
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide123$175,305
OzempicSemaglutide115$165,718
EliquisApixaban89$88,650
JardianceEmpagliflozin39$42,439
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$32,424
JanuviaSitagliptin Phosphate22$21,268
EntrestoSacubitril/Valsartan25$20,738
SymbicortBudesonide/Formoterol Fumarate50$19,836
FarxigaDapagliflozin Propanediol29$18,695
XareltoRivaroxaban23$16,725
CreonLipase/Protease/Amylase25$13,963
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$13,820
MyrbetriqMirabegron11$12,062
BrilintaTicagrelor16$11,892
Albuterol Sulfate HfaAlbuterol Sulfate280$11,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$45$175,305123 claims
Novo NordiskOzempic$88$165,718115 claims
AstraZenecaSymbicort, Farxiga, Brilinta$206$50,42395 claims
Boehringer IngelheimJardiance$17$42,43939 claims
NovartisEntresto$84$20,73825 claims
Johnson & JohnsonXarelto$24$16,72523 claims
AbbVieCreon$291$13,96325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →